Goodwin Procter advised CathWorks on the deal. CathWorks announced its acquisition option agreement and co-promotion agreement with Medtronic (NYSE: MDT). Under the acquisition option agreement, Medtronic will...
CathWorks’ Acquisition Option Agreement and Co-promotion Agreement with Medtronic
Sichuan Kelun-Biotech Biopharmaceutical’s License Agreement with Merck
Goodwin Procter advised Sichuan Kelun-Biotech Biopharmaceutical Co. on the deal. Sichuan Kelun-Biotech Biopharmaceutical Co. announced its exclusive license and collaboration agreement with Merck for ex-China development...
PepGen’s $108 Million Initial Public Offering
Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
Regeneron Pharmaceuticals’ Acquisition of Checkmate Pharmaceuticals
Wachtell, Lipton, Rosen & Katz advised Regeneron on the deal, while Goodwin represented Checkmate Pharmaceuticals. Fried Frank acted as counsel to Centerview Partners, financial advisor to...
Collegium Pharmaceutical’s Acquisition of BioDelivery Sciences International
Goodwin Procter advised BioDelivery Sciences International on the deal while Troutman Pepper advised Collegium Pharmaceutical. BioDelivery Sciences International (NASDAQ: BDSI) announced its definitive merger agreement to be...
Amylyx Pharmaceuticals’ $190 Million IPO
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
Aura Biosciences’ $75.6 Million IPO
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
Omega Therapeutics’ $144.6 Million IPO
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA...
Cerevel Therapeutics’ $350 Million Public Offering
Goodwin Procter advised Cerevel Therapeutics on the deal. Cerevel Therapeutics (Nasdaq: CERE) announced its underwritten public offering of 14,000,000 shares of common stock at a public offering...
Ambrx Biopharma’s $126 Million IPO
Goodwin Procter LLP and JunHe advised Goldman Sachs & Co. LLC and the other underwriters on the deal, while Wilson Sonsini Goodrich & Rosati and Maples...
Femasys’ $34.45 Million IPO
Goodwin Procter advised the underwriters on the deal, while Dechert advised Femasys. Chardan, a global investment bank, announced that it acted as lead left bookrunner in...
HiFiBiO’s $75 Million Series D Financing Round
Goodwin Procter LLP advised HiFiBiO on the deal. HiFiBiO announced its oversubscribed $75 million Series D financing round. HiFiBiO is a multinational biotechnology company with unique expertise...